Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

Wegovy, a weight loss drug made famous by celebrities around the world, is on New Zealand pharmacists' shelves, but it is ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...